On March 15, 2021 Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, reported the company will present at one of the Science/AAAS Webinar Series, "Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment" (Press release, Genetron Health Technologies, MAR 15, 2021, View Source [SID1234576667]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webinar will be available online on March 31. It is now open for registration at:
View Source

Genetron Health’s Chief Technology Officer, Dr. Yuchen Jiao, will discuss the company’s advanced early cancer screening technology and join the conversation with Dr. Anne Marie Lennon, Director of the Johns Hopkins Division of Gastroenterology and Hepatology and a professor of Medicine at the Johns Hopkins University School of Medicine.

Early detection of a cancer is critical to its characterization, treatment, and eventual elimination. Many cancers, however, grow undetected due to the traditional lack of sufficiently accurate or sensitive means to detect them. With recent advances in the detection of cancer-specific DNA in the blood—so-called cell-free DNA, or cfDNA, there is hope that liquid biopsies could provide a minimally invasive way to identify primary cancers much sooner, as well as alert doctors to relapse following treatment by identifying minimal residual disease.

This webinar will discuss these advances in early cancer screening, such as recent successes and new methodologies for cfDNA detection and analysis. Topics will include:

The importance and clinical rationale for early cancer screening, providing examples from liver and pancreatic cancer
How liquid biopsies from blood and other fluids can provide a valuable complement to current standard-of-care tests such as mammography and colonoscopy
Results from recent studies using some of the latest cfDNA detection methodologies
Potential clinical applications for early cancer screening amid the move toward individualized patient treatment
Science has long been one of the most credible and trusted sources of information for scientists around the world. Published by the not-for-profit AAAS, Science – and its growing family of journals – continue to set the standard for original research and news content that scientists have come to depend on.